Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Serum Levels of Sex Steroids and Metabolites Following 12 Weeks of Intravaginal DHEA Administration.

Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur E; participating Members of the Prasterone Clinical Research Group.

J Steroid Biochem Mol Biol. 2015 Aug 17. pii: S0960-0760(15)30049-2. doi: 10.1016/j.jsbmb.2015.08.016. [Epub ahead of print]

PMID:
26291918
2.

Research in academic medical centers: two threats to sustainable support.

Levine AS, Alpern RJ, Andrews NC, Antman K, Balser JR, Berg JM, Davis PB, Fitz JG, Golden RN, Goldman L, Jameson JL, Lee VS, Polonsky KS, Rappley MD, Reece EA, Rothman PB, Schwinn DA, Shapiro LJ, Spiegel AM.

Sci Transl Med. 2015 May 27;7(289):289fs22. doi: 10.1126/scitranslmed.aac5200.

PMID:
26019216
3.

T-SPOT.TB Interferon-γ Release Assay Performance in Healthcare Worker Screening at Nineteen U.S. Hospitals.

King TC, Upfal M, Gottlieb A, Adamo P, Bernacki E, Kadlecek CP, Jones JG, Humphrey-Carothers F, Rielly AF, Drewry P, Murray K, DeWitt M, Matsubara J, O'Dea L, Balser J, Wrighton-Smith P.

Am J Respir Crit Care Med. 2015 Aug 1;192(3):367-73. doi: 10.1164/rccm.201501-0199OC.

PMID:
26017193
4.

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

Stefanutti C, Blom DJ, Averna MR, Meagher EA, Theron Hd, Marais AD, Hegele RA, Sirtori CR, Shah PK, Gaudet D, Vigna GB, Sachais BS, Di Giacomo S, du Plessis AM, Bloedon LT, Balser J, Rader DJ, Cuchel M; Phase 3 HoFH Lomitapide Study Investigators.

Atherosclerosis. 2015 Jun;240(2):408-14. doi: 10.1016/j.atherosclerosis.2015.03.014. Epub 2015 Mar 14.

5.

Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.

Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Côté I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur É; Members of the VVA Prasterone Group.

Maturitas. 2015 May;81(1):46-56. doi: 10.1016/j.maturitas.2015.02.005. Epub 2015 Feb 16.

PMID:
25771041
6.

Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).

Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Côté I, Lavoie L, Martel C, Balser J; other participating members of the VVA Prasterone Group.

Menopause. 2015 Sep;22(9):950-63. doi: 10.1097/GME.0000000000000428.

PMID:
25734980
7.

Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.

Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B.

Ann Oncol. 2015 Apr;26(4):774-9. doi: 10.1093/annonc/mdv010. Epub 2015 Jan 20.

8.

Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.

Bouchard C, Labrie F, Archer DF, Portman DJ, Koltun W, Elfassi É, Grainger DA, Ayotte N, Cooper TA, Martens M, Waldbaum AS, Labrie C, Côté I, Lavoie L, Martel C, Balser J; VVA Prasterone Group.

Climacteric. 2015;18(4):590-607. doi: 10.3109/13697137.2014.992012. Epub 2015 Mar 3.

PMID:
25511551
9.

Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.

Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Gilbert L, Martel C, Balser J.

J Sex Med. 2014 Jul;11(7):1766-85. doi: 10.1111/jsm.12517. Epub 2014 Apr 28.

PMID:
24774442
10.

Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.

Potet F, Lorinc AN, Chaigne S, Hopkins CR, Venkataraman R, Stepanovic SZ, Lewis LM, Days E, Sidorov VY, Engers DW, Zou B, Afshartous D, George AL Jr, Campbell CM, Balser JR, Li M, Baudenbacher FJ, Lindsley CW, Weaver CD, Kupershmidt S.

J Biol Chem. 2012 Nov 16;287(47):39613-25. doi: 10.1074/jbc.M112.380162. Epub 2012 Oct 2.

11.

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S.

J Clin Oncol. 2012 Feb 20;30(6):631-6. doi: 10.1200/JCO.2011.37.4223. Epub 2012 Jan 23.

12.

An inactivated cell-culture vaccine against yellow fever.

Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, Sisti M, Trent DW.

N Engl J Med. 2011 Apr 7;364(14):1326-33. doi: 10.1056/NEJMoa1009303.

13.

Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia.

Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.

Climacteric. 2011 Apr;14(2):282-8. doi: 10.3109/13697137.2010.535226. Epub 2011 Jan 18.

PMID:
21244215
14.

Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary?

Labrie F, Martel C, Balser J.

Menopause. 2011 Jan;18(1):30-43. doi: 10.1097/gme.0b013e3181e195a6.

PMID:
20683211
15.

High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy.

Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Martel C, Balser J.

Gynecol Endocrinol. 2010 Jul;26(7):524-32. doi: 10.3109/09513590903511547.

PMID:
20459349
16.

Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record.

Ritchie MD, Denny JC, Crawford DC, Ramirez AH, Weiner JB, Pulley JM, Basford MA, Brown-Gentry K, Balser JR, Masys DR, Haines JL, Roden DM.

Am J Hum Genet. 2010 Apr 9;86(4):560-72. doi: 10.1016/j.ajhg.2010.03.003. Epub 2010 Apr 1. Erratum in: Am J Hum Genet. 2010 Aug 13;87(2):310.

17.

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.

Jackson LA, Gaglani MJ, Keyserling HL, Balser J, Bouveret N, Fries L, Treanor JJ.

BMC Infect Dis. 2010 Mar 17;10:71. doi: 10.1186/1471-2334-10-71.

18.

Beyond Flexner: a new model for continuous learning in the health professions.

Miller BM, Moore DE Jr, Stead WW, Balser JR.

Acad Med. 2010 Feb;85(2):266-72. doi: 10.1097/ACM.0b013e3181c859fb.

PMID:
20107354
19.

Selective gamma-ketoaldehyde scavengers protect Nav1.5 from oxidant-induced inactivation.

Nakajima T, Davies SS, Matafonova E, Potet F, Amarnath V, Tallman KA, Serwa RA, Porter NA, Balser JR, Kupershmidt S, Roberts LJ 3rd.

J Mol Cell Cardiol. 2010 Feb;48(2):352-9. doi: 10.1016/j.yjmcc.2009.11.016. Epub 2009 Dec 3.

20.

Novel molecular determinants in the pore region of sodium channels regulate local anesthetic binding.

Yamagishi T, Xiong W, Kondratiev A, Vélez P, Méndez-Fitzwilliam A, Balser JR, Marbán E, Tomaselli GF.

Mol Pharmacol. 2009 Oct;76(4):861-71. doi: 10.1124/mol.109.055863. Epub 2009 Jul 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk